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In human saphenous vein endothelial cells (HSVECs), tumor necrosis factor-a (TNFa) and bacterial lipopolysaccharide (LPS), but
neither interferon g (IFNg) nor interleukin 1h (IL-1h), stimulate arginine transport. The effects of TNFa and LPS are due solely to the
enhancement of system y+ activity, whereas system y+L is substantially unaffected. TNFa causes an increased expression of SLC7A2/CAT-
2B gene while SLC7A1/CAT-1 expression is not altered by the cytokine. The suppression of PKC-dependent transduction pathways,
obtained with the inhibitor chelerytrhine, the inhibitor peptide of PKC~ isoform, or chronic exposure to phorbol esters, does not prevent
TNFa effect on arginine transport. Likewise, ERK, JNK, and p38 MAP kinases are not involved in the cytokine effect, since arginine
transport stimulation is unaffected by their specific inhibitors. On the contrary, inhibitors of NF-nB pathway hinder the increase in CAT2B
mRNA and the stimulation of arginine uptake. These results indicate that in human endothelial cells the activation of NF-nB pathway
mediates the TNFa effects on arginine transport.
D 2004 Elsevier B.V. All rights reserved.Keywords: CAT transporter; SLC7 gene; TNFa; NFnB1. Introduction
L-Arginine, the precursor of nitric oxide (NO), enters
mammalian cells through several membrane-bound trans-
porters: system y+, b0, +, B0, +, and y+L [1]. The widely
expressed systems y+ and y+L are referable, respectively, to
the CAT family of monomeric transporters and to the0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2004.04.001
Abbreviations: CAPE, caffeic acid phenethyl ester; CFPD, 2-(4-
chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1, 2-dihydropyrazol-3-
one; DRB, 5,6-diclorobenzimidazole riboside; EBSS, Earle’s balanced salt
solution; FBS, fetal bovine serum; HSVECs, human saphenous vein
endothelial cells; HUVECs, human umbilical vein endothelial cells; IL-1h,
interleukin 1h; IFNg, interferon g; LPS, lipopolysaccharide; M199,
medium 199; MG132, peptide aldehyde Cbz-Leu-Leu-Leucinal; NEM, N-
ethylmaleimide; NOS, nitric oxide synthase; PD98059, 2V-amino-3V-
methoxiflavone; PDTC, pyrrolidine dithiocarbamate; PPM-18, a-benzoy-
lamino 1,4-naphthoquinone; SB203580, 4-(4-fluorophenyl)-2-(4-methyl-
sulfinylphenyl)-5-(4-pyridyl)1H-imidazole; SP600125, anthra [1,9]
pyrazol-6[2H]-one; TNFa, tumor necrosis factor-a
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E-mail address: valeria.dallasta@unipr.it (V. Dall’Asta).recently characterized group of heterodimeric amino acid
transporters (HATs) [2–4]. Systems y+ and y+L can be
easily discriminated, since the former is sensitive to N-
ethylmaleimide (NEM) while the latter can interact with
neutral amino acids, such as leucine, although only in the
presence of sodium [5]. Human umbilical vein endothelial
cells (HUVECs) express CAT-1 and CAT-2B, for system y+,
as well as y + LAT-1, y + LAT-2, and 4F2hc, for system y+L,
and transport arginine through the additive operations of the
two systems [6].
In various cell models, pro-inflammatory mediators, such
as tumor necrosis factor-a (TNFa), interleukin 1h (IL-1h),
and interferon g (IFNg), enhance the expression of CAT
transporters and the influx of arginine [7–9]. Also in
HUVECs, as in other endothelial models [10,11], arginine
transport is stimulated by TNFa through an increase in
CAT-2B expression. On the contrary, the activity and the
expression of system y+L are not changed by the cytokine
[6]. However, the signal transduction mechanisms associat-
ed with CAT induction and transport enhancement have
been poorly characterized in endothelial cells.
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genes through the activation of NF-nB transcription factor
[12]. NF-nB is regulated primarily by phosphorylation of
inhibitory proteins, the InBs, which withhold the factor in
the cytoplasm of non-stimulated cells. In response to TNFa,
InB kinase (InBKK) phosphorylates the InBs that are
ubiquitinated and degraded, thus permitting the nuclear
translocation of the NF-nB [12]. In the nucleus, NF-nB
transcriptional activity can be modulated by several TNFa
responsive protein kinases, such as the p38 subgroup of
MAPKs, providing a cross-talk point with other signaling
pathways [13].
This study was undertaken to identify the transduction
pathways involved in TNFa stimulation of endothelial
arginine transport through system y+. We demonstrate here
that in a model of adult human endothelium, human
saphenous vein endothelial cells (HSVECs), TNFa enhan-
ces the influx of cationic amino acid through the activation
of NF-nB.Fig. 1. Characterization of arginine influx in HSVECs. Cells were washed
twice in EBSS or in Na+-free EBSS (as indicated) and L-arginine influx was
assayed with 30-s incubations in the same solutions containing [3H]arginine
(0.1 mM; 4 ACi/ml). The assay was performed in the absence or in the
presence of 2 mM L-leucine. Where indicated, cells were pretreated for 5
min with 0.5 mM NEM. Points are means of four independent
determinations within one representative experiment with S.D. indicated.
The experiment was performed in three different cell strains with similar
results.2. Materials and methods
2.1. Cells and experimental treatment
Strains of HSVECs were obtained from three distinct
patients undergoing coronary artery bypass grafting as
already described [14]. Cells were routinely grown in
collagen-coated 10-cm diameter dishes in medium 199
(M199), with glutamine concentration raised to 2 mM.
The culture medium was supplemented with 20% fetal
bovine serum (FBS), endothelial cell growth supplement
(50 Ag/ml), and heparin (90 U/ml). The conditions of culture
were as follows: pH 7.4, 5% CO2 in air, and 37 jC. Cultures
consisted of homogeneous endothelial populations, as de-
termined by typical cobblestone morphology and positivity
to von Willebrand’s factor and CD31 antigens [14]. Three
strains of HSVECs were isolated, characterized, and
employed for the investigations presented here with quali-
tatively similar results. Culture medium was always
renewed 24 h before the experiment.
For stimulation, all the cytokines and LPS (from E. coli,
serotype O55:B5) were added from 100 stock solutions
in water to complete growth medium for the times indicated
for each experiment. As shown through routinely performed
determinations of culture protein content or cell number, no
significant cell loss was observed up to 48 h under the
experimental conditions employed.
When inhibitors were required by the experimental pro-
tocols, they were added 1 h before TNFa treatment from
100 stock solutions in water or in growth medium.
2.2. Arginine influx
The experiments were carried out on HSVEC subcultures
resulting from 3.5 104 cells seeded into 2-cm2 wells ofdisposable Falcon 24-well trays (Becton Dickinson Labware
Europe, Le Pont De Claix, France) in 1 ml of growth
medium. Cells were employed after 2–3 days when cultures
were almost confluent (15F 2 Ag of protein/cm2). All the
experiments were performed using the cluster-tray method
for the measurement of solute fluxes in adherent cells [15]
with appropriate modifications. Cell monolayers were
washed twice in Earle’s balanced salt solution (EBSS),
containing (in mM) 117 NaCl, 26 NaHCO3, 5 KCl, 1.8
CaCl2, 1 NaH2PO4, 0.8 MgSO4, 5.5 glucose. L-Arginine
uptake was determined from the initial influx of L-arginine,
assayed with a 30-s incubation of the cells in the same
solution containing L-[3H]arginine. The experiments were
terminated by three rapid washes ( < 10 s) in ice-cold urea
(300 mM). Cell monolayers were extracted in 0.2 ml of
ethanol, and the radioactivity of extracts was determined
with a Wallac Microbeta Trilux. Extracted cell monolayers
were then dissolved with 0.5% sodium deoxycholate in 1 M
NaOH, and protein content was determined directly in the
well using a modified Lowry procedure [15]. Preliminary
characterization experiments (shown in Fig. 1) indicated that
HSVEC, like HUVECs [6], transport arginine through two
Na+-independent components: one, insensitive to N-ethyl-
maleimide (NEM) and suppressed by excess L-leucine in the
presence of sodium, corresponds to system y+L; the other,
inhibited by NEM and relatively insensitive to leucine, is
identifiable with system y+. Therefore, when both systems
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sensitive, leucine-resistant fraction of arginine transport,
while NEM-insensitive, leucine inhibitable fraction repre-
sented the activity of system y+L. When only the activity of
system y+ had to be determined, arginine uptake was
measured in the presence of sodium and in the presence
of leucine 2 mM, a treatment that completely abolished
uptake through system y+L. Arginine influx is expressed as
nmol/mg protein/min1.
2.3. Reverse transcription
Total RNA from subconfluent cultures grown in 10-cm2
wells was isolated with TRIZOLR (Life Technologies,
Milan, Italy). RNA (2 Ag), pretreated with RNAse-free
DNAse, heated at 70 jC for 10 min, and placed on ice for
1 min, was incubated with a mixture containing 0.5 mM
dNTPs mix, 25 ng/Al Oligo(dT)15–18 (Life Technologies),
10 mM dithiothreitol, 1 first-strand buffer, 40 units of
RNAse inhibitor (Amersham Biotech, Milan, Italy), 200
units of SuperScript RT (Life Technologies), and water to a
final volume of 20 Al for 1 h at 42 jC. The reaction was
stopped by heating at 70 jC for 15 min. The duplex of
RNA–DNA was treated with 2 units of RNAse H (US
Biochemicals, Cleveland, OH) at 37 jC for 20 min, and the
amount of single-strand cDNA was evaluated using the
fluorescent probe Oligreen (Molecular Probes, Eugene,
OR) and phage M13+ as single-strand DNA standard with
a Victor2 1420 Multilabel Counter, Wallac.
2.4. Polymerase chain reaction and ‘‘semi-quantitative
PCR’’
For PCR, 100 ng of single-strand cDNA from each
sample was amplified in a total volume of 25 Al with 1 U
of Platinum Taq DNA Polymerase (Invitrogen S.r.L., Milan,
Italy), 1.6 PCR buffer, 0.2 mM each dNTPs, 1.5 mM
MgCl2, along with both glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and proband sense and antisense
primers employed at a concentration of 0.1 AM each. The
primers were designed according to the sequences reported
in GenBank with the help of Primer 3 program [16]. Primers
for CAT-1 were 5V-ACT TGC TTC TAT GCC TTC GTG
(sense) and 5V-TGT GGC GAT TAT TGG TGT TT (anti-
sense) yielding an amplicon of 387 bp. The other primers
were the same employed previously (see Table 1 of Ref.
[6]). The sense primers for CAT-2B cDNA recognize the
unique sequence resulting from the alternative splicing of
the SLC7A2 transcript. A hot start PCR technique was
utilized to reduce formation of nonspecific amplification
products. An initial denaturation step at 92 jC for 2 min was
followed by 34 cycles, with a 2-min denaturation step at 94
jC, the annealing at 59 jC for 30 s, and the extension step at
72 jC for 1 min. Another cycle was carried out, with the
only difference being the final extension of 5 min. In
preliminary experiments, these conditions were selected soas to verify that the PCR products were in the exponential
phase of amplification for all the proband and GAPDH
transcripts. Amplified mixtures (10 Al) were electrophoresed
through a 2% agarose gel (NuSieve 3:1-FMC), stained with
ethidium bromide (0.5 Ag/ml) in 0.5 TBE buffer (0.1 M
Tris, 90 mM boric acid, and 1 mM EDTA, pH 8.4), and
visualized by ultraviolet light. Product size was established
by co-migration with a 100-bp ladder marker (Bio-Rad
Laboratories, Milan, Italy). Images of the electrophoresed
cDNAs were recorded with a digital DC 120 Kodak camera
and quantified by ID Image Analysis Software (Kodak
Digital Science).
To confirm the identity with the reported human sequen-
ces, PCR products were ligated into pCRII-TOPO vector
(TOPO TA cloning, Invitrogen BV, Groningen, The Nether-
lands) and used to transform CaCl2 competent E. coli.
Plasmid DNAwas extracted with Jetquick plasmid miniprep
spin kit (Genomed GmbH, Bad Oeynhausen, Germany);
both sense and antisense strands of the cDNA were se-
quenced (MWG-Biotech AG, Ebersberg, Germany).
2.5. Statistical analysis
Statistical analysis of transport data was performed with
analysis of variance, unless otherwise stated. The compar-
ison between densitometry results of RT-PCR in control and
treated cells was performed with the Wilcoxon test for
nonparametric data.
2.6. Materials
FBS was purchased from Euroclone (Milan, Italy) and
Medium 199 from Life Technology Italia (Milan, Italy). L-
[2,3,4-3H]Arginine (45–70 Ci/mmol) was obtained from
DuPont de Nemours (Bad-Homburg, Germany), TNFa,
anthra [1,9-cd] pyrazol-6 [2H]-one (SP600125), and 2-(4-
chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1 (CFPD)
from Alexis (San Diego, CA); other NF-nB inhibitors,
peptide aldehyde Cbz-Leu-Leu-Leucinal (MG132), 2V-ami-
no-3V-methoxiflavone (PD98059), the PKC~ pseudosub-
strate inhibitor peptide, and 4-(4-Fluorophenyl)-2-(4-
methylsulf inylphenyl)-5-(4-pyridyl)1H- imidazole
(SB203580) from Calbiochem; Sigma (St. Louis, MO) was
the source of E. coli (serotype O55:B5) lipopolysaccharide
(LPS) as well as of all other chemicals.3. Results
3.1. Effect of cytokines and LPS on arginine influx in
HSVEC cells
In the experiment shown in Fig. 2, the effect of pro-
inflammatory cytokines and LPS on the discriminated influx
of arginine was studied in HSVECs. Treatments were
prolonged for 48 h in complete growth medium and arginine
Fig. 2. Effect of pro-inflammatory cytokines and LPS on the discriminated
influx of L-arginine. Cells were incubated in the absence (control, o) or in
the presence of 1 Ag/ml LPS (n), 10 ng/ml TNFa, (.), 10 ng/ml IL-1h (x)
or 5 ng/ml IFNg (z). After the indicated times, cells were washed twice in
EBSS and L-arginine influx was assayed with 30-s incubations in the same
solution in the presence of [3H]arginine (0.1mM; 4ACi/ml) both in cells
pretreated for 5 min with 0.5 mM NEM (NEM-resistant influx) and in
untreated cells (total influx). Panel A: System y+. Data represent the NEM-
sensitive arginine influx calculated at any indicated time as the difference
between total and NEM-resistant influx. Panel B: System y+L. NEM-
resistant arginine influx. Points are means of four independent determi-
nations within one representative experiment with S.D. indicated. The
experiment was repeated four times employing two different cell strains
with similar results.
Fig. 3. Effect of DRB on TNFa-induced increase of system y+ activity
transport. HSVECs, grown to confluence in Medium 199, were incubated
with TNFa (10 ng/ml) for 9 h. DRB (50 AM) was added 1 h before the
treatment with the cytokine. Cells were washed twice in EBSS and the
transport activity of system y+ was assayed by 30-s incubations in the same
solution containing [3H]arginine (0.1 mM; 4 ACi/ml) supplemented with L-
leucine (2 mM). Data are means of three independent determinations, with
S.D. indicated, obtained in a representative experiment repeated three times
employing two different cell strains.
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exposed or unexposed to NEM. Both TNFa and LPS
produced an increase of L-arginine transport through the
sole NEM-sensitive component, i.e. system y+ (Panel A).
System y+ stimulation required at least 6 h of treatment and
was maximal after 9 h. At this time the Vmax of the system
was almost doubled in treated cells (1.62F 0.119 vs.
3.08F 0.126 nmol/mg protein/min in untreated and
TNFa-treated cells, respectively). After 24 h, NEM-sensi-
tive arginine influx was still significantly higher in treated
cells than in control cells and returned to basal values only
after 48 h of treatment. In contrast, IL-1h and INFg had no
effect on arginine transport through system y+. No signifi-
cant change was detected for NEM-resistant component, i.e.
system y+L, under any of the experimental conditions tested
(Panel B). After 9 h of incubation the Vmax of the system
was 2.06F 0.182 vs. 1.97F 0.378 nmol/mg protein/min in
untreated and TNFa-treated cells, respectively.
To ascertain if the increase of L-arginine transport in-
duced by TNFa were dependent on macromolecular syn-
thesis, we suppressed transcription with DRB. The inhibitor,
added 1 h before treatment, substantially hindered TNFa-
induced increase of system y+ transport activity without
altering the basal uptake of arginine (Fig. 3).
3.2. Effects of TNFa on the expression of genes for cationic
amino acid transporters in HSVECs
A preliminary analysis of the expression of genes in-
volved in high affinity system y+ in HSVECs, performed
with RT-PCR, indicated that this endothelial modelexpresses SLC7A1, for CAT-1 transporter, and SLC7A2,
for CAT-2B transporter (results not shown). Fig. 4 reports
the RT-PCR of system y+-related genes (panels A and B),
along with the densitometric analyses of the products (Panel
C), obtained in HSVECs incubated in the presence of TNFa.
The relative abundance of SLC7A1/CAT-1 RT-PCR product
to GAPDH product remained constant throughout the treat-
ment until 48 h. In contrast, the ratio of SLC7A2/CAT-2B to
GAPDH increased after 4 h of incubation, reached a
fourfold stimulation at 24 h, and decreased thereafter. The
Wilcoxon test carried on with all the RT-PCR analyses
performed on different cell strains revealed a highly signif-
icant increment (P < 0.01) of CAT-2B expression at all the
times of treatment considered, except for the 48-h time
point.
RT-PCR products of the y+L-related genes SLC7A6
(coding for y + LAT-2 protein), SLC7A7 (for y + LAT-1),
and SLC3A2 (for 4F2hc) did not show any significant
variation with either TNFa or LPS (not shown).
3.3. Involvement of kinases in TNFa-dependent stimulation
of system y+ activity
Several inhibitors were used to assess the involvement of
intracellular kinase cascades in TNFa-dependent stimulation
of system y+ transport activity. As shown in Fig. 5, Panel A,
the stimulation of system y+ by TNFa was unaffected by the
MAPK inhibitors PD98059, a flavone compound which
prevents ERK1/2 activation, SB 203580 and CFPD, both
inhibitors of p38MAPK, and by SP600125, a novel inhibitor
Fig. 4. Effect of TNFa on the expression of genes related to system y+ in
HSVECs. Cultures were incubated for the indicated times in the presence of
10 ng/ml of TNFa before RNA extraction. After reverse transcription,
cDNA was used as template for PCR co-amplification reactions in which
GAPDH primers were employed together with primers for SLC7A1/CAT-1
(Panel A) or SLC7A2/CAT-2B (Panel B). After the electrophoresis of RT-
PCR products, gels were stained with ethidium bromide and photographed.
Panel C reports the densitometric analysis in which the relative intensity of
the SLC7A1 and SLC7A2/CAT-2B amplification products was normalized
to those of the co-amplified GAPDH product. The analysis, repeated twice
in three different cell strains, yielded comparable results.
Fig. 5. Effect of kinase inhibitors on the TNFa-induced stimulation of
system y+ transport activity. After the preincubation in the presence of the
various inhibitors and TNFa treatment, cells were washed twice in EBSS
and the transport activity of system y+ was assayed as described in Fig. 3.
Data are means of three independent determinations, with S.D. shown,
obtained in a representative experiment repeated three times employing two
different cell strains. Panel A: Effects of MAPK inhibitors. Cells were
incubated with PD98059 (50 AM), SB 203580 (20 AM), SP600125 (5 AM),
or CFPD (15 AM), 1 h before the treatment with TNFa that was prolonged
for 9 h in the presence of the same inhibitors. Panel B: Effects of PKC
inhibitors. Cells were preincubated with chelerytrine (5 AM) for 1 h, PKC~
inhibitor peptide (10 AM) for 1 h, or PDBu (100 nM) for 24 h. After the
preincubation, cells were treated with TNFa for 9 h in the presence of the
same inhibitors.
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by any of the inhibitor tested.
Three distinct approaches were employed to evaluate the
role of PKC in TNFa-induced stimulation of system y+
transport activity. The first consisted in the chronic exposure
to 100 nM PDBu, a treatment that down-regulates protein
kinase C activity [18,19]. For the second approach, TNFa-
treatment was performed in the presence of the specific
inhibitor chelerythrine employed at 5 lM, the maximal
concentration found to be nontoxic in HSVECs (R. Visi-
galli, unpublished results). Third, TNFa treatment was
performed in the presence of the inhibitor peptide for PKCf,
an atypical PKC isozyme poorly sensitive to phorbol-
induced PKC down-regulation. TNFa stimulation of system
y+ transport activity was still clearly detectable under all the
three conditions adopted (Fig. 5, Panel B).
3.4. Effects of NF-jB and proteasome inhibitors on system
y+ activity and CAT-2B mRNA expression
To investigate the involvement of NF-jB in TNFa
stimulation on system y+ activity, we studied the effect of
different inhibitors of the transcription factor. We haveselected inhibitors with different mechanisms of action,
such as caffeic acid phenethyl ester (CAPE) and pyrrolidine
dithiocarbamate (PDTC) that inhibit NF-jB activation sup-
pressing the interaction of NF-jB proteins with the DNA
[20]; PPM-18 that blocks the removal of IjBa from NF-
jB/IjBa complex [21]; and MG132 that inhibits the pro-
teasome-dependent degradation of IjB [22], thus preventing
the nuclear translocation of the transcription factor.
As shown in Fig. 6, no inhibitor had significant effects on
arginine transport in the absence of TNFa. Conversely, in
the presence of TNFa, all the inhibitors markedly hindered
the influx of the cationic amino acid. PDTC, CAPE, and
MG132 completely suppressed the stimulatory effect of the
Fig. 6. TNFa-induced stimulation of system y+ transport activity:
sensitivity to NF-nB inhibitors. HSVECs were pretreated for 1 h with the
indicated NF-nB inhibitors: CAPE (25 Ag/ml), PPM-18 (1 AM), PDTC
(100 AM), MG132 (2 AM) and then stimulated with 10 ng/ml TNFa for 9
h in the presence of the same inhibitors. The transport activity of system y+
was determined as described in Fig. 3. Data are means of three independent
determinations, with S.D. indicated, obtained in a representative experiment
repeated three times employing two different cell strains. **P < 0.01
(inhibitor present vs. inhibitor absent in TNFa-treated cells). oP < 0.05
(TNFa-present vs. TNFa-absent in inhibitor-treated cells).
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modify significantly system y+ transport activity. On the
contrary, PPM-18 inhibited the effect of the cytokine only
partially. Consistently, RT-PCR analysis indicated that
PPM-18 markedly reduced, but did not abolish, the induc-
tion of CAT-2B caused by TNFa (Fig. 7). The Wilcoxon test
carried on with all the RT-PCR analyses performed on
different cell strains revealed a highly significant increment
(P < 0.01) of CAT-2B expression for TNFa-treated cells and
a significant increment (P < 0.05) for TNFa-treated cells
incubated in the presence of the inhibitor.Fig. 7. Effect of PPM-18 on the expression of SLC7A2/CAT-2B induced by
TNFa. Cultures were pretreated for 1 h with PPM-18 (1 AM) and then
stimulated with 10 ng/ml TNFa for 9 h in the presence of the same
compound. RNA extraction, reverse transcription, and co-amplification
were performed as detailed in Section 2. After electrophoresis of RT-PCR
products, the gel was stained with ethidium bromide and photographed
(Panel A). Panel B reports the densitometric analysis of SLC7A2/CAT-2B
amplification products, normalized to those of the co-amplified GAPDH
product. The analysis, repeated twice in two different cell strains, yielded
comparable results.4. Discussion
Although the intracellular concentration of arginine is
well above the Km of nitric oxide synthase (NOS) for the
cationic amino acid, endothelial transport of arginine could
represents a key factor for the appropriate fueling of the
synthase under conditions of increased NO production [23].
Previous work performed with endothelial cells from human
umbilical veins or from bovine aorta [6,10] has demonstrat-
ed the sensitivity of endothelial transport of arginine to pro-
inflammatory cytokines. With endothelial cells obtained
from saphenous veins (HSVECs), a model of adult human
endothelium in vitro, we demonstrate that neither IFNg nor
IL-1h have significant effects on arginine transport and
point to TNFa and LPS as major factors for the up-
regulation of arginine transport during the inflammatory
response. As in HUVECs [6], also in HSVECs system y+is the sole target of TNFa. In the former model, no
expression of CAT-2B is observed under control conditions
and the gene is induced by the cytokine. In HSVECs, CAT-
2B transcript is expressed at low levels even under control
conditions and markedly increased by the cytokine. How-
ever, in both endothelial models, neither the expression of
the genes related to system y+L nor the activity of the
transport system itself is sensitive to any pro-inflammatory
compound. Interestingly, an increased abundance of CAT-
2B mRNA, associated with a stimulated arginine transport
through system y+, but not through system y+L, has been
also detected in human peripheral blood mononuclear cells
obtained from patients with septic shock [24].
Previous work from this laboratory [6] has yielded a
characterization of arginine transport in human endothelium
in vitro and demonstrated that high extracellular concen-
trations of leucine can be employed as a convenient exper-
imental condition to restrict the transport of the cationic
amino acid to system y+. With this simple experimental
device, we have measured the discriminated activity of
system y+ and demonstrated that the enhancement of argi-
nine transport induced by the cytokine requires the activa-
tion of NF-nB. Inhibitors of this transduction pathway
hinder the transport stimulation, independently of their
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of NF-nB CAPE and PDTC and the proteasome inhibitor
MG132, completely suppress arginine transport stimulation
by TNFa. In contrast, another NF-nB inhibitor, PPM-18,
does not abolish the effect of the cytokine. In this case, also
the increase in CAT-2B mRNA is only partially suppressed,
indicating that a good correlation exists between CAT-2B
mRNA levels and TNFa stimulation of arginine transport
through system y+. The involvement of NF-nB on the
stimulation of arginine transport by inflammatory com-
pounds, previously demonstrated only in non-endothelial
models [25], adds CAT-2 gene to the enlarging list of targets
of the transcription factor.
The study has been extended to ascertain if other
transduction pathways are involved in the NF-nB-dependent
stimulation of arginine transport by TNFa. MAPK cascades
could be good candidates for such a role since it is known
that TNFa activates these transduction pathways in endo-
thelial cells [26–28]. Moreover, short-term stimulation of
arginine influx via system y+ by adenosine [29] and D-
glucose [30] is blocked by the inhibition of p44/42 MAPK
in HUVECs. The stimulation of arginine transport by LPS
in smooth muscle cells also appears to involve MAPK, and
in particular p38 [31]. Nevertheless, inhibitors of the main
MAPK groups, ERK1/2, p38, and JNK, do not interfere
with TNFa stimulation of endothelial arginine transport,
even if employed, as in the case of PD98059 and
SB203580, at relatively high concentrations. These results,
therefore, exclude an involvement of these transduction
pathways in the stimulatory effect of the cytokine.
Also PKC isozymes may intervene in the transduction of
TNFa signal that leads to the increased expression of CAT-
2B transporter. The classical PKCa, the novel PKCq, and the
atypical PKC~ have been demonstrated in HSVECs [18] and
the two former isozymes, but not PKC~ , are stimulated by
TNFa [18]. In HUVECs PKC inhibition counteracts the
effects of TNFa treatment on the expression of adhesion
molecules [32]. Moreover, in one of the first reports
concerning cytokine-mediated stimulation of arginine trans-
port in HUVECs [33], the effect is blocked by chelerythrine,
a PKC inhibitor endowed with poor isoform specificity. In
contrast with that contribution [33], the results presented
here indicate that chelerythrine does not hinder TNFa
stimulation of arginine transport in HSVECs. Also the
long-term exposure to phorbol esters, an experimental con-
dition associated with the down-regulation of classical and
novel PKC isozymes [19], does not affect the stimulation of
system y+ activity by TNFa. Moreover, the possibility that,
as for other effects of TNFa [34], the cytokine activates
system y+ through PKC~ , an atypical PKC insensitive to
phorbols, has been further excluded through the employment
of the specific inhibitor peptide. No PKC isozyme appears,
therefore, to be requested for TNFa effect on arginine
transport in HSVECs. Whether the discrepancy is due to
difference in the endothelial model employed and/or to
possible differences in the isozyme pattern is not clear. Thesedata do not imply that endothelial arginine transport is PKC-
insensitive. Recent results indicate that the down-regulation
of classical PKC isoform, obtained with an 18-h exposure
to phorbols, indeed produces an increase in arginine trans-
port [19]. In contrast, the results reported in this contribu-
tion indicate that down-regulation of PKC does not change
appreciably arginine uptake. However, it should be stressed
that although Krotova et al. [19] attribute changes in
transport to modifications of system y+ activity, no discrim-
ination of arginine transport was reported in that paper.
Therefore, PKC effects on arginine transport in endothelial
deserve further investigations.
In conclusion, this report demonstrates that, in human
endothelial cells, NF-nB activation is required for TNFa-
dependent stimulation of the expression of CAT-2B trans-
porter while neither MAPK nor PKC appear to be involved
in the regulatory mechanism.Acknowledgements
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